Each year, the American Heart Association (AHA), in conjunction with the Centers for Disease
Control and Prevention, the National Institutes of Health, and other government agencies, …

Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …

BACKGROUND Mucositis is a highly significant, and sometimes dose‐limiting, toxicity of
cancer therapy. The goal of this systematic review was to update the Multinational Association …

Each year, the American Heart Association (AHA), in conjunction with the Centers for Disease
Control and Prevention, the National Institutes of Health, and other government agencies, …

Each year, the American Heart Association (AHA), in conjunction with the Centers for Disease
Control and Prevention, the National Institutes of Health, and other government agencies, …

… , to consume ≥4.5 cups/d of fruits and vegetables, ≥2 servings/wk of fish, and ≥3 servings/d
of whole grains and no more than 36 oz/wk of sugar-sweetened beverages and 1500 mg/…

Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose
cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …

Background The cardiovascular safety and efficacy of many current antihyperglycemic agents,
including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. Methods We …

Background Data are lacking on the long-term effect on cardiovascular events of adding
sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and …

Tobacco and alcohol use are leading causes of mortality that influence risk for many complex
diseases and disorders 1 . They are heritable 2 , 3 and etiologically related 4 , 5 behaviors …